Innate Pharma(IPHA)
$1.59+0.05 (+3.31%)
IPHA
Innate Pharma financials statements
$1.59
At close:+0.05 (+3.31%)
Want to see IPHA full AI Analyst Report?
Innate Pharma (IPHA) Ratios
155 Followers
Innate Pharma Ratios
IPHA's free cash flow for Q2 2026 was €-21.42M. For the 2026 fiscal year, IPHA's free cash flow was decreased by €-91.21K and operating cash flow was €-21.33M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.27 | 2.60 | 3.73 | 3.38 | 1.73 |
| Quick Ratio | 1.27 | 2.60 | 3.73 | 3.38 | 1.73 |
| Cash Ratio | 0.77 | 2.01 | 1.78 | 2.04 | 1.30 |
| Solvency Ratio | -0.52 | -0.46 | -0.02 | -0.08 | -0.30 |
| Operating Cash Flow Ratio | -0.89 | -0.21 | -0.82 | -0.46 | -0.73 |
| Short-Term Operating Cash Flow Coverage | -3.82 | -0.82 | -3.85 | -15.17 | -1.95 |
| Net Current Asset Value | € -37.70M | € -16.48M | € 15.72M | € -13.88M | € -21.80M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.28 | 0.23 | 0.20 | 0.17 |
| Debt-to-Equity Ratio | -1.04 | 3.51 | 0.77 | 0.78 | 0.41 |
| Debt-to-Capital Ratio | 25.98 | 0.78 | 0.43 | 0.44 | 0.29 |
| Long-Term Debt-to-Capital Ratio | -1.70 | 0.72 | 0.37 | 0.42 | 0.10 |
| Financial Leverage Ratio | -2.89 | 12.57 | 3.38 | 3.84 | 2.49 |
| Debt Service Coverage Ratio | -4.87 | -5.21 | -0.20 | -7.92 | -1.43 |
| Interest Coverage Ratio | -121.42 | -91.12 | -19.80 | -199.39 | -153.29 |
| Debt to Market Cap | 0.17 | 0.21 | 0.18 | 0.14 | 0.13 |
| Interest Debt Per Share | 0.26 | 0.39 | 0.48 | 0.53 | 0.56 |
| Net Debt to EBITDA | 0.13 | 0.75 | 16.70 | 3.42 | 1.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 10.83% | 10.42% | -184.12% |
| EBIT Margin | -1748.73% | -387.49% | -13.35% | -100.02% | -394.86% |
| EBITDA Margin | -1566.06% | -371.69% | -3.54% | -21.29% | -356.91% |
| Operating Profit Margin | -1916.94% | -408.64% | -24.41% | -99.57% | -394.86% |
| Pretax Profit Margin | -1764.51% | -391.97% | -14.59% | -100.52% | -375.48% |
| Net Profit Margin | -1764.51% | -391.97% | -14.59% | -100.74% | -436.01% |
| Continuous Operations Profit Margin | -1764.51% | -391.97% | -14.59% | -100.52% | -375.48% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.23% | 116.12% |
| EBT Per EBIT | 92.05% | 95.92% | 59.75% | 100.95% | 95.09% |
| Return on Assets (ROA) | -78.44% | -44.54% | -4.32% | -27.95% | -19.74% |
| Return on Equity (ROE) | 226.68% | -560.01% | -14.59% | -107.30% | -49.15% |
| Return on Capital Employed (ROCE) | -205.02% | -66.06% | -9.35% | -34.48% | -25.49% |
| Return on Invested Capital (ROIC) | -153.25% | -59.43% | -8.77% | -34.05% | -21.90% |
| Return on Tangible Assets | -78.44% | -44.54% | -4.33% | -28.16% | -23.65% |
| Earnings Yield | -36.93% | -34.35% | -3.55% | -20.96% | -16.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.37 | 7.68 | 1.12 | 18.36 | 7.30 |
| Payables Turnover | 0.00 | 6.56 | 6.54 | 3.78 | 3.19 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.64 | 2.46 | 8.21 | 6.75 | 1.19 |
| Asset Turnover | 0.04 | 0.11 | 0.30 | 0.28 | 0.05 |
| Working Capital Turnover Ratio | 0.09 | 0.16 | 0.50 | 0.74 | 0.13 |
| Cash Conversion Cycle | 996.65 | -8.12 | 271.16 | -76.60 | -64.35 |
| Days of Sales Outstanding | 996.65 | 47.52 | 326.94 | 19.88 | 50.02 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 55.63 | 55.78 | 96.48 | 114.38 |
| Operating Cycle | 996.65 | 47.52 | 326.94 | 19.88 | 50.02 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.36 | -0.09 | -0.39 | -0.24 | -0.73 |
| Free Cash Flow Per Share | -0.39 | -0.09 | -0.42 | -0.25 | -0.75 |
| Dividend Paid and CapEx Coverage Ratio | -13.85 | -17.64 | -13.85 | -17.07 | -43.95 |
| Capital Expenditure Coverage Ratio | -13.85 | -17.64 | -13.85 | -17.07 | -43.95 |
| Operating Cash Flow Coverage Ratio | -1.44 | -0.22 | -0.82 | -0.45 | -1.32 |
| Operating Cash Flow to Sales Ratio | -11.68 | -0.55 | -0.63 | -0.33 | -4.83 |
| Free Cash Flow Yield | -26.21% | -5.06% | -16.38% | -7.31% | -18.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.81 | -2.91 | -28.15 | -4.77 | -6.04 |
| Price-to-Sales (P/S) Ratio | 47.79 | 11.41 | 4.11 | 4.81 | 26.34 |
| Price-to-Book (P/B) Ratio | -6.14 | 16.30 | 4.11 | 5.12 | 2.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.81 | -19.76 | -6.10 | -13.67 | -5.34 |
| Price-to-Operating Cash Flow Ratio | -4.09 | -20.88 | -6.54 | -14.48 | -5.46 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | -0.01 | 0.32 | -0.17 | -0.00 |
| Enterprise Value Multiple | -2.92 | -2.32 | -99.16 | -19.16 | -6.00 |
| Enterprise Value | 127.66M | 108.62M | 182.35M | 235.28M | 259.47M |
| EV to EBITDA | -2.92 | -2.32 | -99.16 | -19.16 | -6.00 |
| EV to Sales | 45.81 | 8.61 | 3.51 | 4.08 | 21.42 |
| EV to Free Cash Flow | -3.66 | -14.91 | -5.22 | -11.60 | -4.34 |
| EV to Operating Cash Flow | -3.92 | -15.75 | -5.60 | -12.28 | -4.44 |
| Tangible Book Value Per Share | -0.24 | 0.11 | 0.51 | 0.66 | 0.80 |
| Shareholders’ Equity Per Share | -0.24 | 0.11 | 0.62 | 0.68 | 1.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.16 | 0.62 | 0.72 | 0.15 |
| Net Income Per Share | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 |
| Interest Burden | 1.01 | 1.01 | 1.09 | 1.00 | 0.95 |
| Research & Development to Revenue | 15.65 | 4.12 | 1.08 | 0.90 | 3.88 |
| SG&A to Revenue | 3.95 | 0.95 | 0.23 | 0.25 | 1.32 |
| Stock-Based Compensation to Revenue | 1.53 | 0.31 | 0.08 | 0.07 | 0.22 |
| Income Quality | 4.30 | 0.14 | 4.30 | 0.33 | 1.11 |
Currency in EUR
